Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer

Suppression of gonadal testosterone synthesis represents the standard first line therapy for treatment of metastatic prostate cancer. However, in the majority of patients who develop castration-resistant prostate cancer (CRPC), it is possible to detect persistent activation of the androgen receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Mark N, Patel, Neal, Bershadskiy, Alexander, Sokoloff, Alisa, Singer, Eric A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023364/
https://www.ncbi.nlm.nih.gov/pubmed/24759590
http://dx.doi.org/10.4103/1008-682X.129133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023364/
https://www.ncbi.nlm.nih.gov/pubmed/24759590
http://dx.doi.org/10.4103/1008-682X.129133

Ejemplares similares